👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 98/100
Accepting new patients
Prof
Prof Michael Dickinson
Haematology
English
12,494+
Patients seen
6
Years in practice
10
Publications
1
Languages spoken
About
Professor Michael Dickinson is Lead of the Aggressive Lymphoma stream and provides care for patients with all forms of lymphoma, myeloma, myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). He convenes the Lymphoma Multidisciplinary Meeting (MDM), serves as Deputy Clinical Lead of the CAR-T Centre of Excellence, and is Chair of the Lymphoma Working Party of the Australasian Leukaemia and Lymphoma Group, as well as Chair of the Clinical Research Committee at Peter MacCallum Cancer Centre.
Professor Dickinson has a strong focus on drug development and early-phase clinical trials. As Principal Investigator, he has treated the first patient globally in multiple first-in-human studies and has helped take several novel therapies through to registration. He treated the first patients worldwide in trials of glofitamab, a bispecific antibody for lymphoma, as well as epigenetic agents such as BET inhibitors, NKX019 (CAR-NK cells), YTB323 (rapcabtagene autoleucel), and ELARA, a CAR-T registration trial for follicular lymphoma. His team were the first to use YESCARTA and KYMRIAH both in clinical trials and commercially in Australia, and were the highest ex-US recruiters to pivotal CAR-T trials in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
He was the lead investigator in the registration trial of the first-in-class agent glofitamab and has authored more than 100 peer-reviewed publications, including in the New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood. Professor Dickinson is committed to mentoring research fellows and PhD students, supporting their academic and professional development.
Professor Dickinson has a strong focus on drug development and early-phase clinical trials. As Principal Investigator, he has treated the first patient globally in multiple first-in-human studies and has helped take several novel therapies through to registration. He treated the first patients worldwide in trials of glofitamab, a bispecific antibody for lymphoma, as well as epigenetic agents such as BET inhibitors, NKX019 (CAR-NK cells), YTB323 (rapcabtagene autoleucel), and ELARA, a CAR-T registration trial for follicular lymphoma. His team were the first to use YESCARTA and KYMRIAH both in clinical trials and commercially in Australia, and were the highest ex-US recruiters to pivotal CAR-T trials in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
He was the lead investigator in the registration trial of the first-in-class agent glofitamab and has authored more than 100 peer-reviewed publications, including in the New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood. Professor Dickinson is committed to mentoring research fellows and PhD students, supporting their academic and professional development.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof Michael Dickinson
Education & training
-
2010–2016 MD · Medicine and Surgery
-
2016–2020 Residency · Haematology
-
2020–2021 Fellowship · Subspecialty training
Career & appointments
-
2020-09–2021-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Haematology
Malpractice insurance:
AXA Healthcare Liability · 1,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,937 |
| Annual physical exam | 99395 | 599 |
| Vaccination administration | 90471 | 999 |
| Minor procedure (skin) | 17110 | 2,824 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 60 min | in_clinic | 720.00 EUR |
| Minor procedure (skin) | 90 min | in_clinic | 630.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 5 · i10: 14
-
European registry analysis of Haematology outcomes
DOI: 10.1445/euroclin.2025.0 · PMID: 36635456 · cited by 57
-
Outcomes of Haematology in adults — a multi-centre cohort
DOI: 10.1337/euroclin.2024.1 · PMID: 33786571 · cited by 19
-
European registry analysis of Haematology outcomes
DOI: 10.2422/euroclin.2023.2 · PMID: 39308798 · cited by 13
-
Outcomes of Haematology in adults — a multi-centre cohort
DOI: 10.3698/euroclin.2022.3 · PMID: 35597386 · cited by 199
Invited talks
- Practical updates in Haematology European Annual Congress (Haematology) · Vienna · 2024 · invited
- Single-centre experience in Haematology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Haematology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2021
- national college of family doctors — Member · since 2021
- European Union of Medical Specialists (UEMS) — Member · since 2021
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.75
- Staff Friendliness
- 5.00
- Ease Of Appointment
- 4.90
- Value For Money
- 4.92
- Would Recommend Pct
- 99
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Haematology
- Awareness When should you see a haematology?
For international patients
- Coordinator
- Patient liaison · michael.dickinson@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
